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Abstract 
G-protein subunit α-11 (Gα11) couples the calcium-sensing receptor (CaSR) to phospholipase 
C (PLC)-mediated intracellular calcium (Ca2+i) and mitogen-activated protein kinase (MAPK) 
signaling, which in the parathyroid glands and kidneys regulates parathyroid hormone release 
and urinary calcium excretion, respectively. Heterozygous germline loss-of-function Gα11 
mutations cause familial hypocalciuric hypercalcemia type 2 (FHH2), for which effective 
therapies are currently not available. Here, we report a novel heterozygous Gα11 germline 
mutation, Phe220Ser, which was associated with hypercalcemia in a family with FHH2. 
Homology modelling showed the wild-type Phe220 non-polar residue to form part of a cluster 
of hydrophobic residues within a highly conserved cleft region of Gα11, which binds to and 
activates PLC; and predicted that substitution of Phe220 with the mutant Ser220 polar 
hydrophilic residue would disrupt PLC-mediated signalling. In vitro studies involving transient 
transfection of wild-type and mutant Gα11 proteins into HEK293 cells, which express the 
CaSR, showed the mutant Ser220 Gα11 protein to impair CaSR-mediated Ca2+i and 
extracellular signal-regulated kinase 1/2 (ERK) MAPK signaling, consistent with diminished 
activation of PLC. Furthermore, engineered mutagenesis studies demonstrated that loss of 
hydrophobicity within the Gα11 cleft region also impaired signalling by PLC. The loss-of-
function associated with the Ser220 Gα11 mutant was rectified by treatment of cells with 
cinacalcet, which is a CaSR positive allosteric modulator. Furthermore, in vivo administration 
of cinacalcet to the proband harbouring the Phe220Ser Gα11 mutation, normalised serum 
ionized calcium concentrations. Thus, our studies, which report a novel Gα11 germline mutation 
(Phe220Ser) in a family with FHH2, reveal the importance of the Gα11 hydrophobic cleft region 
for CaSR-mediated activation of PLC, and show that allosteric CaSR modulation can rectify 
the loss-of-function Phe220Ser mutation and ameliorate the hypercalcemia associated with 
FHH2. This article is protected by copyright. All rights reserved 
Keywords: Parathyroid-related disorders; DISORDERS OF CALCIUM/PHOSPHATE 
METABOLISM; THERAPEUTICS; CELL/TISSUE SIGNALING- Endocrine Pathways 
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Introduction 
G-protein subunit alpha-11 (Gα11) is a major downstream signalling partner of the cell-surface 
calcium-sensing receptor (CaSR), which is a family C G-protein coupled receptor (GPCR) that 
plays a pivotal role in the parathyroid and renal regulation of extracellular calcium (Ca2+e) 
concentrations(1). Gα11 belongs to the Gq/11 class of G-proteins that enhance phospholipase C 
(PLC) activity, thereby leading to formation of: inositol 1,4,5-trisphosphate (IP3), which 
induces rapid increases in intracellular Ca2+ (Ca2+i) concentrations; and enhances 
diacylglycerol (DAG) formation, which in turn activates protein kinase C and the mitogen-
activated protein kinase (MAPK) signalling cascade(2,3). These signal transduction events allow 
the CaSR to respond to small fluctuations in the prevailing Ca2+e concentrations ([Ca2+]e) and 
to induce alterations in parathyroid hormone (PTH) secretion and urinary calcium excretion(4).  
 
The identification of germline heterozygous mutations of Gα11, which is encoded by the 
GNA11 gene on chromosome 19p13.3,
 
that result in familial hypocalciuric hypercalcemia 
(FHH) has demonstrated the importance of this G-protein subunit in Ca2+e homeostasis(5). FHH 
is an autosomal dominant disorder characterized by lifelong elevations of serum calcium 
concentrations in association with normal or mildly raised serum PTH concentrations and low 
urinary calcium excretion (calcium-to-creatinine clearance ratio <0.01)(4). FHH comprises 
three genetically distinct conditions, designated as FHH types 1-3. FHH1 (OMIM #145980) is 
caused by loss-of-function CaSR mutations(1). FHH2 (OMIM #145981) is caused by loss-of-
function Gα11 mutations; to date, three FHH2-associated mutations have been reported, 
comprising two missense mutations, Thr54Met and Leu135Gln, and an in-frame isoleucine 
deletion at codon 200 (Ile200del)(5,6) (Supplemental Figure 1). FHH3 (OMIM #600740) is 
caused by loss-of-function mutations of the adaptor protein-2 sigma-1 (AP2S1) gene, encoding 
AP2σ, which is involved in the clathrin-mediated endocytosis of GPCRs, such as the CaSR(1).  
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Positive allosteric modulators of the CaSR, known as calcimimetics, represent a targeted 
therapy for patients with symptomatic FHH. Indeed, cinacalcet, a licenced calcimimetic drug, 
has been used to ameliorate symptomatic hypercalcemia in patients with FHH1 and FHH3(7-9). 
However, such effects of cinacalcet in FHH2 patients have not been reported, although 
cinacalcet has been shown in vitro, to rectify signaling abnormalities associated with FHH2-
causing Gα11 mutations(10). Here, we report the effectiveness of cinacalcet in ameliorating the 
signalling defects and hypercalcemia due to a previously unreported FHH2-associated Gα11 
mutation, Phe220Ser. 
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Materials and Methods   
Case Report 
The proband (individual II.1, Figure 1A) was a 33 year old male who presented with headaches, 
constipation and pruritus. Biochemical investigations revealed hypercalcemia, 
hypophosphatemia, raised plasma PTH concentrations, and a low calcium-to-creatinine 
clearance ratio (Table 1). A DXA scan showed normal bone mineral density values at the spine 
and hip (Table 1). A skin biopsy, undertaken to investigate the pruritus, demonstrated 
folliculitis (Table 1). His father, and three of his four children, also had hypercalcemia, 
constipation and/or headaches (Table 1). Two of his affected children had eczema, and the 
proband’s father had sustained an osteoporotic vertebral fracture. The familial hypercalcemia 
and reduced urinary calcium excretion were consistent with FHH, however CASR or AP2S1 
mutations were not identified. Informed consent was obtained from individuals and where 
appropriate, parents and guardians of children, using protocols approved by the Research 
Ethics Committee of the Helsinki University Hospital.  
 
Mutational Analysis 
DNA sequence analyses of GNA11 exons 1-7 and adjacent splice sites (NM_002067) was 
performed using leucocyte DNA and gene-specific primers (SigmaAldrich), as previously 
reported(5,6). Polymorphic variants were identified from public databases (Supplemental Table 
1).   
Protein Sequence Alignment and Three-Dimensional Modeling of Gα11 Structure  
Protein sequences of Gα11 orthologs were aligned using ClustalOmega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/)(6). Gα11 three-dimensional modeling was 
undertaken using the reported three-dimensional structures of: Gαq in complex with 
phospholipase C-β3 (Protein Data Bank accession no. 3OHM)(11); Gαq in complex with the 
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small molecule inhibitor YM-254890 (Protein Data Bank accession no. 3AH8)(12); and Gαq in 
complex with the regulator of G-protein signaling 2 (RGS2) (Protein Data Bank accession no. 
4EKC and 4QJ3)(13,14). The Gαq protein, which shares 90% identity at the amino acid level with 
Gα11, was used because crystal structures of Gα11 are not available. Figures were prepared 
using the PyMOL Molecular Graphics System, Schrodinger. 
 
Cell culture and Transfection  
Mutations were introduced into the previously described pBI-CMV2-GNA11 expression 
construct by site-directed mutagenesis using the Quikchange Lightning Kit (Agilent 
Technologies) and gene-specific primers (SigmaAldrich). Wild-type or mutant pBI-CMV2-
GNA11 constructs were transiently transfected into HEK293 cells stably expressing CaSR 
(HEK293-CaSR) using Lipofectamine 2000 (LifeTechnologies), as described(15,16). The pBI-
CMV2-GNA11 bidirectional vector allows for co-expression of Gα11
 
and GFP at equivalent 
levels(5). HEK293-CaSR cells were maintained in DMEM-Glutamax media (Gibco) that has a 
calcium concentration of 1.80 mM.  The presence of mutations was verified using 
dideoxynucleotide sequencing with the BigDye Terminator v3.1 Cycle Sequencing Kit (Life 
Technologies) and an automated detection system (ABI3730 Automated capillary sequencer; 
Applied Biosystems)(17). Luciferase reporter constructs (pGL4.30-NFAT, pGL4.33-SRE) were 
purchased from Promega. HEK293 cells were used because suitable parathyroid and renal 
tubular cells are not available, and HEK293 cells have been established as a model for the 
functional expression of Gα11 proteins(5,15,16). HEK-CaSR cells were cultured in high-glucose 
DMEM (Invitrogen) supplemented with 10% fetal bovine serum and 1% geneticin at 37°C, 5% 
CO2(5). Successful transfection was confirmed by visualising GFP fluorescence using an 
Eclipse E400 fluorescence microscope with an epifluorescence filter, and images were 
captured using a DXM1200C digital camera and NIS Elements software (Nikon)(5,16). The 
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expression of Gα11 and CaSR proteins was confirmed by Western blot analyses using Gα11 
(Santa Cruz Biotechnologies), anti-calnexin (Millipore) or anti-CaSR (Abcam) antibodies. 
Calnexin, a housekeeping protein, was used as a loading control. The Western blots were 
visualised using an Immuno-Star Western C kit (BioRad) on a BioRad Chemidoc XRS+ 
system(6). 
 
Fluo-4 intracellular calcium assay 
Ca2+e-induced Ca2+i responses were measured by Fluo-4 calcium assays adapted from methods 
previously published(18). HEK-CaSR cells were plated in poly-L-lysine treated black-walled 
96-well plates (Corning), and transiently transfected with 1000ng/ml pBI-CMV2-GNA11. 
Cells were conditioned in serum-free media (1.8 mM Ca2+e) overnight, then incubated in Ca2+- 
and Mg2+-free Hanks Balanced Salt Solution (HBSS) for 1 hour, followed by loading with 
Fluo-4 dye, prepared according to manufacturer’s instructions (Invitrogen). Cells were loaded 
for 40 minutes at 37°C, then either: a 20% aqueous solution of 2-hydoxypropyl-β-cyclodextrin 
(vehicle); or 30 or 100 nM cinacalcet was added. Cells were then incubated for a further 20 
minutes at 37°C(18). Baseline measurements were made and CaCl2 was injected into each well 
to increase the [Ca2+]e in a stepwise manner from  0.5-10mM [Ca2+]e, using an automated 
system. Changes in Ca2+i were recorded on a PHERAstar instrument (BMG Labtech) at 37°C 
with an excitation filter of 485nm and an emission filter of 520nm. The peak mean fluorescence 
ratio of the transient response after each individual stimulus was measured using MARS data 
analysis software (BMG Labtech), and expressed as a normalized response. Nonlinear 
regression of concentration-response curves was performed with GraphPad Prism using the 
normalized response at each [Ca2+]e for each separate experiment for the determination of the 
EC50 (i.e. [Ca2+]e required for 50% of the maximal response). Assays were performed in 4-12 
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biological replicates for each of the expression constructs. Statistical analysis was performed 
using the F-test(5,6).  
 
Luciferase reporter assay 
HEK-CaSR cells were seeded in 48-well plates and transiently transfected with 100ng/mL pBI-
CMV2-GNA11 wild-type (WT) or mutant proteins, 100ng/ml luciferase construct (either 
pGL4-NFAT or pGL4-SRE) and 10ng/ml pRL control vector for 48 hours. Cells were 
incubated in serum-free media for 12 hours, followed by treatment of cells for 4 hours with 
0.1-10mM CaCl2. Cells were lysed and assays performed with Dual-Glo luciferase (Promega) 
on a Veritas Luminometer (Promega), as previously described(19). Luciferase:renilla ratios were 
expressed as fold-changes relative to responses at basal CaCl2 concentrations. For studies with 
cinacalcet (Cambridge Bioscience), the drug was added to cells, as described previously(10,19). 
All assays were performed using 4 biological replicates on up to 3 independent occasions. 
Statistical analysis was performed by 2-way ANOVA with Tukey’s multiple-comparisons test 
using GraphPad Prism 6. 
 
Measurement of ERK phosphorylation 
HEK-CaSR cells were seeded in 48-well plates and transfected with 200ng/mL WT or mutant 
Gα11, 48-hours prior to performance of assays. Transfected cells were incubated in serum-free 
media 12 hours prior to treatment of cells with 0.1-10mM CaCl2. Cells were then lysed in 
Surefire lysis buffer, and AlphaScreen Surefire ERK assays measuring phosphorylated and 
total proteins were performed, as previously described(10,19). The fluorescence signal in both 
assays was measured using the PHERAstar FS microplate reader (BMG Labtech)(19). The ratio 
of phosphorylated ERK to total ERK measured at each [Ca2+]o were normalized to the mean 
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responses of WT expressing cells and expressed as a fold-change of responses obtained at basal 
(0.1 mM) [Ca2+]e. All assay conditions were performed in 4 biological replicates on up to 4 
independent occasions.  Statistical analysis was performed by 2-way ANOVA with Tukey’s 
multiple-comparisons test using GraphPad Prism 6.   
 
Web Resources 
Predicted effect of the mutation was assessed using Polyphen-2 
(http://genetics.bwh.harvard.edu/pph2/)(20) and MutationTasting 
(http://www.mutationtaster.org/)(21). 
 
Statistics 
All studies involved between 4-16 separate transfection experiments. Statistical analyses for 
Ca2+i EC50 used the F-test(19), and two-way ANOVA with Tukey’s multiple-comparisons test 
was used for pERK and luciferase reporter assays. Analyses were undertaken using GraphPad 
Prism, and a value of p<0.05 was considered significant.   
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Results 
 
Identification of a novel Phe220Ser Gα11 mutation in a family with FHH2 
DNA sequence analysis of GNA11 in the proband identified a heterozygous T-to-C transition 
at nucleotide c.659 (Figure 1A), resulting in a missense substitution of the WT Phe to a mutant 
Ser at residue 220 of the Gα11 protein. Bioinformatic analyses predicted the Phe220Ser variant 
to be damaging and likely disease-causing (Polyphen-2 score = 1, MutationTasting score = 
0.99). The absence of this DNA sequence abnormality in >67,200 exomes from the NHLBI-
ESP and Exome Aggregation Consortium cohorts, together with evolutionary conservation of 
the Phe220 residue in Gα11 orthologs and Gα-subunit paralogs (Figure 1B), also indicated that 
the Phe220Ser abnormality likely represents a pathogenic mutation rather than a benign 
polymorphic variant.  
  
The Phe220Ser mutation is located in the switch II region of Gα11 and predicted to impair 
PLC activation  
Homology modelling, using crystal structures of the related Gαq protein(11,12,22), revealed the 
WT Phe220 residue to be located within the α2-helix of the flexible switch II region of the Gα11 
GTPase domain (Figure 1B-C, Supplemental Figure 1), and to comprise part of a hydrophobic 
cluster of amino acids located within a cleft region formed by switch II and the adjacent α3-
helix that interact with PLC upon G-protein activation (Figure 1C-D)(11). Substitution of the 
non-polar hydrophobic WT Phe220 residue, with the mutant polar hydrophilic Ser220 residue 
is predicted to disrupt Gα11 function by impairing PLC activation and signaling.  
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The Gα11 Phe220Ser mutation impairs Ca2+i responses 
The Phe220Ser mutation is predicted to diminish PLC activation, and we therefore assessed its 
effects on Ca2+i mobilization, which has previously been shown to be enhanced downstream of 
PLC by the Gq/11 proteins(23-26). HEK293 cells stably expressing the CaSR (HEK-CaSR) were 
transiently transfected with pBI-CMV2-GNA11 constructs expressing the WT (Phe220) or 
mutant (Ser220) Gα11 proteins (Supplemental Figure 2). The Ca2+i responses of the mutant 
Ser220 Gα11-expressing HEK-CaSR cells, revealed that a significantly greater [Ca2+]e was 
required to achieve half-maximal (EC50) Ca2+i responses, when compared with WT-expressing 
cells (Figure 2A). Thus, the Ser220 mutant-expressing cells showed a rightward shift in the 
concentration-response curve, with a significantly elevated mean EC50 value (p<0.001) of 2.93 
mM (95% confidence interval (CI), 2.80-3.07 mM), compared with 2.40 mM (95% CI, 2.27-
2.53 mM) for WT expressing cells. The Ca2+i responses were also assessed by measurement of 
nuclear factor of activated T-cells (NFAT), which is a downstream mediator of Ca2+i 
signalling(27). NFAT fold-change responses were determined using a luciferase reporter assay, 
and these studies showed that HEK-CaSR cells expressing the Ser220 Gα11 mutant had a 
significantly reduced fold-change response (fold-change = 2.3±0.3) following exposure to 
5mM [Ca2+]e, when compared with WT cells (fold-change = 4.8±0.4, p<0.001) (Figure 2B). 
These data demonstrated that the Gα11 Phe220Ser mutation impairs CaSR-mediated Ca2+i 
responses, consistent with a loss-of-function associated with FHH2.  
 
The Gα11 Phe220Ser mutation impairs ERK phosphorylation 
The ERK protein represents a major component of the MAPK signaling cascade, which has 
previously been demonstrated to be activated by PLC (3,28). We assessed the effect of the Gα11 
Phe220Ser mutation on ERK phosphorylation by measuring phosphorylated ERK (pERK) in 
response to increases in Ca2+e in WT and mutant Ser220 Gα11 expressing cells using the 
AlphaScreen assay, and also by assessing serum-response element (SRE)-mediated 
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transcriptional activity, which is regulated by ERK signalling(19). The pERK responses of the 
Ser220 Gα11 mutant were shown to be significantly reduced. Thus, the Ser220 Gα11 mutant led 
to significant reductions in: pERK-to-total ERK ratios (Ser220 response at 5mM Ca2+e = 
3.7±0.4 versus Phe220 = 6.1±0.3, p<0.0001) (Figure 2C); and to SRE reporter fold-changes 
(Ser220 fold-change at 5mM Ca2+e = 6.5±0.5 versus Phe220 fold-change = 11.8±0.7, 
p<0.0001) (Figure 2D). Thus, the Gα11 Phe220Ser mutation impaired CaSR-mediated ERK 
phosphorylation. 
 
Phe220 forms part of a hydrophobic cluster of Gα11 residues required for PLC-mediated 
signalling 
To further determine the mechanistic role of the Phe220 residue and the importance of residue 
220 hydrophobicity for Gα11 function and PLC-mediated signalling (Figure 1C), we engineered 
mutations of Phe220 to Leu and Ala, which are hydrophobic residues, and to Arg and Glu, 
which are hydrophilic positively- and negatively-charged residues, respectively, and studied 
their effect on Ca2+i and ERK responses following transient expression in HEK-CaSR cells 
(Figure 3). The Leu220 and Ala220 Gα11 mutants did not alter Ca2+i responses (Figure 3A-B, 
Supplemental Figure 3), or ERK activity, as measured using the pERK AlphaScreen and SRE 
reporter assays (Figure 3C-D). In contrast, the positively-charged Arg220, and negatively-
charged Glu220 Gα11 mutants, respectively, enhanced and impaired Ca2+i and ERK signalling 
responses in HEK-CaSR cells (Figure 3, Supplemental Figure 3). Thus, these findings 
demonstrated that a hydrophobic residue at position 220 is required for signalling via PLC. The 
enhancement of CaSR-mediated signaling by the Arg220 Gα11 mutant may be explained by its 
structural effect on the G11 heterotrimer. Homology modelling, using crystal structures of the 
related Gq protein in complex with Gβγ(12) revealed that the Arg220 residue faces away from 
the hydrophobic cluster, into the region at which Gα and Gβγ bind, a hydrophobic region that 
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is necessary for Gα activation(29) (Supplemental Figure 4). Disruption of this hydrophobic 
region has previously been shown to cause constitutive activation(29), and modelling predicts 
that the Arg220 residue, which is charged and hydrophilic, disrupts this region, thus enhancing 
activation by impairing Gαβγ association (Supplemental Figure 4). To investigate the 
importance of the Gα11 hydrophobic cleft, formed by switch II and the α3-helix (Figure 1C-D), 
for PLC activation, we engineered mutations of three other hydrophobic residues, Ile217, 
Val223 and Trp263, within this region, to either an Ala residue, to retain hydrophobicity, or to 
a Glu residue, to lose hydrophobicity, and studied the effects of these mutants on Ca2+i and 
ERK responses following their transient expression in HEK-CaSR cells (Supplemental Figure 
5). This demonstrated that substitution to Ala of only one hydrophobic residue, Ile217, altered 
PLC-mediated signaling (Figure 4A-C, Supplemental Figure 6). In contrast, substitution of any 
of the Ile217, Val223 and Trp263 hydrophobic residues to a Glu residue led to a significant 
reduction in Ca2+i and ERK responses (Figure 4D-F, Supplemental Figure 6). Thus, 
hydrophobicity of the switch II-α3 cleft is important for PLC activation.  
 
Cinacalcet rectifies the impaired PLC signalling responses and hypercalcemia caused by 
the Phe220Ser Gα11 mutation 
To determine whether cinacalcet may be an effective therapy for FHH2, we evaluated the 
effects of different cinacalcet concentrations (0, 30 and 100nM) on the altered PLC signaling 
responses due to the Phe220Ser Gα11 mutant. Treatment of mutant Ser220 Gα11-expressing 
HEK-CaSR cells with 30nM cinacalcet, failed to normalize the impaired Ca2+i and SRE 
reporter responses (Figure 5A-C); however, 100 nM cinacalcet, reduced the EC50 values, and 
increased NFAT and SRE reporter activity (Figure 5A-C), such that these values were not 
significantly different from untreated WT cells. These in vitro findings suggested that higher 
doses of cinacalcet may be required for the treatment of patients harboring the Phe220Ser Gα11 
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mutation. Cinacalcet was administered to the FHH2 proband as he had symptoms such as 
headaches, constipation and pruritus (Table 1), which may have been caused by the 
hypercalcemia. The proband was initially commenced on 30 mg/day of oral cinacalcet for 3 
months, and in keeping with the above cellular studies, which showed a lack of efficacy when 
using low cinacalcet concentrations, the 30mg/day dose failed to normalize his elevated serum 
calcium concentrations (Figure 5D). However, increasing the dose of cinacalcet to 60 mg/day, 
successfully lowered the serum concentrations of: ionized calcium from 1.42 to 1.26 mmol/L 
(normal range 1.16-1.30 mmol/L) (Figure 5D); and PTH from 98 to 58 ng/L (normal range 8-
73 ng/L). Although the proband became normocalcemic on cinacalcet, the pruritus, from which 
he suffered the most, did not resolve, and cinacalcet 60 mg/day was discontinued after 4 
months. His hypercalcemia returned upon cessation of cinacalcet therapy (Figure 5D).  
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Discussion 
Our studies have identified a previously unreported FHH2-causing heterozygous Gα11 
germline loss-of-function mutation that represents the first loss-of-function Gα11 mutation to 
be located within the Gα-subunit switch regions. The switch regions are comprised of three 
flexible peptide loops, which are highly conserved amongst all classes of Gα-subunits, and 
undergo substantial conformational changes depending on the guanine nucleotide-bound state 
of the Gα subunit(30). In the GTP-bound state, these peptide loops switch their conformation to 
one that facilitates coupling with downstream effector proteins(31). The Phe220Ser mutation is 
located in the switch II region, which is predicted to bind and activate PLC(11), and our in vitro 
assessment of Ca2+i and pERK responses in cells expressing the mutant Ser220 Gα11 
demonstrated an impairment of signalling that is, at least in part, mediated by PLC(26,32). 
Furthermore, our mutagenesis studies showed that Phe220 forms part of a group of 
hydrophobic residues that are required for coupling to PLC, and that Phe220 is located in a key 
region within this hydrophobic cleft, such that substitution of the hydrophobic Phe220 residue 
for a hydrophilic positively (Arg) or negatively (Glu) charged residue resulted, respectively, in 
a gain- or loss-of Gα11 function, thereby indicating that mutations of Phe220 can either retard 
or enhance the switch II conformational changes that occur upon G-protein activation.  
 
These studies have involved a comprehensive investigation of the effect of FHH2-associated 
Gα11 mutations on PLC signalling at both the cytosolic (i.e. Ca2+i and pERK) and 
transcriptional (i.e. NFAT and SRE reporter) level, and demonstrate that all readouts are 
affected by FHH2 mutations. The need to measure several signal outputs is increasingly 
important as recent studies have shown that GPCRs can couple to multiple G-proteins to 
enhance their signaling capabilities and respond in diverse tissues(33,34). Indeed, this is 
particularly the case in Gα11 mutant cells, where it has been hypothesised that other G-proteins, 
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in particular Gαq, may compensate for some of the functions of Gα11 giving rise to the milder 
phenotype observed in FHH2(5,6). Our studies of the transcriptional events downstream of CaSR 
activation indicate that Ca2+i signaling is more severely impaired than ERK signalling, as the 
Ser220 Gα11 mutant cells have more robust SRE signals than NFAT signals. MAPK signalling 
is known to occur downstream of several G-proteins and can be used as a surrogate to assess 
multiple G-protein families(32,35). The differences observed in Ca2+i signaling compared to ERK 
signaling in Gα11 Ser220 mutant cells indicates that Gα11 may preferentially signal via Ca2+i, 
or that other G-proteins are able to compensate for a reduction in Gα11-mediated ERK 
responses in FHH2 mutant cells. 
 
The Gα11 protein is considered to be ubiquitously expressed(36), thus raising the possibility that 
germline Gα11 mutations may be associated with non-calcitropic phenotypes. Indeed, in 
addition to constipation most of the affected family members had folliculitis or eczematous 
skin lesions, which may potentially represent a non-calcitropic phenotype of FHH2. This is 
plausible as somatic activating Gα11 mutations have been reported to cause cutaneous 
pigmentatory disorders such as dermal melanocytosis (37), and studies of atopic dermatitis, 
which is characterised by impaired epithelial barrier function and eczematous skin lesions, have 
revealed that Gq/11-coupled chemokine receptors facilitate the migration of inflammatory cells 
within the dermis (38). However, such roles of loss-of-function Gα11 mutations in cutaneous 
disorders remain to be elucidated, and these may be facilitated by studies of additional FHH2 
patients and appropriate mouse models. 
 
Our studies have also demonstrated that cinacalcet-mediated allosteric modulation of the CaSR 
successfully rectified the loss-of-function associated with the Phe220Ser Gα11 mutation in vitro 
and in vivo. However, a higher concentration of cinacalcet was required to normalise the 
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signalling responses of cells expressing the Gα11 mutant Ser220, when compared to other 
FHH2-causing Gα11 mutants(10). These in vitro findings suggest that loss-of-function mutations 
located within the Gα11 switch regions may alter the efficacy of calcimimetic compounds, and 
it is notable that the hypercalcemic proband with a Phe220Ser Gα11 mutation required an 
increase in the dose of cinacalcet from 30 to 60 mg daily to normalize the elevated serum 
calcium concentrations (Figure 2C). Moreover, cinacalcet in the patient exerted an inhibitory 
effect on PTH secretion, as observed by a normalization of serum PTH concentrations. 
Cinacalcet may be rectifying the impaired signaling by the mutant Phe220Ser Gα11 by 
increasing signaling through the WT Gα11, which is present endogenously in HEK293 cells 
and the cells of the heterozygous patient, and/or compensatory signaling by the closely-related 
Gαq, which activates the same signaling pathways downstream of CaSR. Importantly, 
hypocalcemia or adverse effects such as nausea and vomiting, which may affect >25% of 
patients(39), were not observed in the patient, despite receiving a higher dose of cinacalcet.  
 
In conclusion, we have identified a FHH2-causing mutation, which affects the Gα11 switch 
region and disrupts PLC-mediated signaling, and have also shown that cinacalcet can rectify 
these signaling disturbances and be used successfully to treat the hypercalcemia caused by this 
germline loss-of-function Gα11 mutation.  
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Figure Legends 
Figure 1. Identification and structural assessment of a Phe220Ser Gα11 mutation in a family 
with familial hypocalciuric hypercalcemia type 2. (A) The family comprised of 5 affected and 
3 unaffected members (Top). The proband (individual II.1) is indicated by an arrow. A 
heterozygous T-to-C transition at nucleotide c.659, predicted to result in a missense 
substitution of the wild-type (WT) Phe to a mutant (m) Ser at codon 220 of the Gα11 protein, 
was identified in the proband and confirmed to cosegregate with hypercalcemia by Sanger 
DNA sequence analysis. (B) Multiple protein sequence alignment of residues comprising the 
β3-α2 loop, α2-helix and α2-β4 loop that form switch II (red box) of Gα11 orthologs (top) and 
Gα-subunit paralogs (bottom). Conserved residues are shown in gray, and WT (Phe, F) and 
mutant (Ser, S) residues are shown in red. (C) Structural model showing that Phe220 of Gα11 
is part of a hydrophobic cluster of amino acids (yellow) within switch II and the α3-helix, which 
stabilize the region in a conformation that facilitates effector binding. (D) Close-up view of 
Phe220 residue, within the switch II region of the GTPase domain of Gα11, in complex with 
phospholipase C-β3 (brown space-filling model), with directly interacting residues of the α2 
and α3 helices colored blue.  
 
Figure 2. Effect of the mutant Ser220 Gα11 on Ca2+i and ERK signalling in HEK-CaSR cells. 
(A) Ca2+i responses to changes in [Ca2+]e of HEK-CaSR cells expressing WT (Phe220) or 
mutant (Ser220) Gα11 proteins shown as the mean±SEM of 4-11 transfections. The Ser220 
Gα11 mutant caused a rightward shift in the Ca2+i concentration-response curve with 
significantly increased EC50 value compared to WT cells (***p<0.0001, F-test). (B) [Ca2+]e-
induced NFAT reporter responses, which are activated by elevations of Ca2+i, were assessed in 
HEK-CaSR cells expressing WT or mutant Gα11 proteins. Responses at each [Ca2+]e are 
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expressed as a fold-change of basal [Ca2+]e responses, and shown as mean±SEM of 12 
transfections. NFAT luciferase reporter activity increased in all cells in a concentration-
dependent manner, and was significantly reduced in Ser220 cells compared to WT cells. (C) 
Ca2+e-induced pERK responses of cells expressing WT or mutant Gα11 protein, expressed as a 
ratio to total ERK levels, and shown as mean±SEM of 8 transfections. (D) Ca2+e-induced SRE 
reporter responses of cells expressing WT or mutant Gα11 protein, expressed compared to basal 
SRE reporter activity, and shown as mean±SEM of 8 transfections. The Ser220 Gα11 mutant 
was associated with significantly decreased pERK and SRE reporter responses compared to 
WT. **p<0.01 and ****p<0.0001, by a 2-way ANOVA with Tukey’s multiple-comparisons 
test. 
 
Figure 3. Effect of Gα11 residue 220 hydrophobicity on PLC-mediated signalling. (A) 
Histograms showing Ca2+e-induced Ca2+i EC50 values with 95% confidence intervals (CI) for 
cells expressing WT Phe220 or residue 220 mutant (m) Gα11 proteins from 6-12 transfections. 
Statistical analyses were performed using the F-test. The Arg220 Gα11 mutant reduced the EC50 
value, whereas the Glu220 and Ser220 Gα11 mutants elevated the EC50 value. (B) Ca2+e-induced 
NFAT reporter responses, which assess Ca2+i signaling, of cells expressing WT or residue 220 
mutant Gα11 proteins. Responses at each [Ca2+]e are expressed as a fold-change of basal [Ca2+]e 
responses, and shown as mean±SEM of 4-12 transfections. NFAT luciferase reporter activity 
increased in all cells in a concentration-dependent manner, however responses were 
significantly elevated in Arg220 Gα11 mutant, and reduced in Glu220 Gα11 mutant cells, 
compared to WT cells. (C) Ca2+e-induced pERK responses of cells expressing WT or mutant 
residue 220 Gα11 proteins, expressed as a ratio to total ERK levels. The Arg220 mutant was 
associated with significantly increased responses, and the Glu220 and Ser220 mutants were 
associated with decreased responses, when compared to WT. Data are shown as mean±SEM 
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of 4-8 independent transfections. (D) Ca2+e-induced SRE reporter responses of cells expressing 
WT or mutant (m) residue 220 Gα11 proteins, expressed as a ratio to total ERK levels. The 
engineered Arg220 mutant was associated with significantly increased, and the engineered 
Glu220 and FHH2-associated Ser220 mutants resulted in decreased responses, when compared 
to WT. Data are shown as mean±SEM of 4-8 independent transfections. Statistical analyses 
performed using 2-way ANOVA with Tukey’s multiple-comparisons test comparing WT with 
Gα11 mutants Ala220, Arg220, Glu220, and Ser220. *p<0.05, **p<0.01, ***p<0.001 
****p<0.0001. 
 
Figure 4. Effect of mutating residues within the Gα11 switch II-α3 hydrophobic cluster on PLC-
mediated signalling. (A) Histograms showing Ca2+e-induced Ca2+i EC50 values with 95% CI 
for cells expressing WT and alanine (Ala) Gα11 mutants (m) of residues 217, 223 and 263 Gα11 
proteins from 4-8 independent transfections. Only the Ala217 Gα11 mutant increased the EC50 
value, when compared to WT cells. Statistical analyses were performed using the F-test. (B-
C) Ca2+e-induced (B) NFAT and (C) SRE luciferase reporter responses of cells expressing WT 
or alanine (Ala) Gα11 mutants. Responses at each [Ca2+]e are expressed as a fold-change of 
basal [Ca2+]e responses, and shown as mean±SEM of 4-8 transfections. NFAT and SRE 
reporter responses were significantly reduced in Ala217 expressing cells compared to WT cells. 
(D) Histograms showing Ca2+e-induced Ca2+i EC50 values with 95% CI for cells expressing WT 
and glutamic acid (Glu) Gα11 mutants (m) of residues 217, 223 and 263 from 4-8 independent 
transfections. All Glu Gα11 mutants increased the EC50 value, when compared to WT cells. 
Statistical analyses were performed using the F-test. (E-F) Ca2+e-induced (E) NFAT and (F) 
SRE luciferase reporter responses
 
of cells expressing WT or glutamic acid (Glu) Gα11 mutants. 
Responses at each [Ca2+]e are expressed as a fold-change of basal [Ca2+]e responses, and shown 
as mean±SEM of 4-8 transfections. NFAT and SRE reporter responses were significantly 
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reduced in cells expressing all 3 glutamic acid mutants compared to WT cells. Statistical 
analyses for panels B, C, E and F were performed using 2-way ANOVA with Tukey’s multiple-
comparisons test comparing WT to mutant 217 (green), 223 (red) and 263 (gray) Gα11 proteins. 
*p<0.05, ***p<0.001, ****p<0.0001.  
 
Figure 5. Effect of cinacalcet on the loss-of-function and hypercalcemia caused by the 
Phe220Ser Gα11 mutation. (A) Effect of cinacalcet on Ca2+i responses to changes in [Ca2+]e of 
HEK-CaSR cells transfected with WT or Ser220 Gα11 mutant (m). The Ca2+i responses to 
changes in [Ca2+]e are expressed as a percentage of the maximum normalized responses and 
shown as the mean±SEM of 6-12 independent transfections. The Ser220 Gα11 mutant led to a 
rightward shift in the concentration-response curve. The addition of 30 nM cinacalcet, a 
concentration previously shown to rectify the loss-of-function associated with the reported 
Leu135Gln Gα11 FHH2 mutant in vitro (10), had no effect on Ser220 responses. However, 
addition of 100 nM cinacalcet rectified the rightward shift of the Ser220 Gα11 mutant, such that 
it was not different to WT responses. (B-C) Histograms showing (B) NFAT and (C) SRE 
luciferase reporter activity in response to 5mM Ca2+e in HEK-CaSR cells expressing WT or 
Ser220 mutant constructs, treated with vehicle or cinacalcet (CIN). Data are shown as 
mean±SEM of 4 independent transfections. 100 nM cinacalcet was required to significantly 
increase NFAT and SRE reporter activity to WT levels. The responses of cells expressing WT 
or mutant Gα11 proteins were compared using the F-test for panel A and 2-way ANOVA with 
Tukey’s multiple-comparisons test for panel B and C. **p<0.01, ***p<0.001, ****p<0.0001. 
(D) Effect of cinacalcet on the serum ionized calcium concentrations of the FHH2 proband 
(individual II.1, Figure 1A) with the Phe220Ser Gα11 mutation. Arrows indicate initiation of 
oral cinacalcet at 30 mg/day (CIN 30), at 60 mg/day (CIN 60), and its discontinuation. 
Cinacalcet treatment decreased serum concentrations of ionized calcium and PTH from 98 ng/L 
(pre-treatment) to 58 ng/L (post-treatment) (normal range 8-73 ng/L). Shaded area indicates 
normal range.  
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Table 1. Clinical and biochemical findings in available affected members of the family 
with the Phe220Ser Gα11 mutation. 
 
Variable Individual 
 II.1 III.2 III.3 III.4 
Sex Male Female Male Female 
Age at diagnosis 33 years 7 weeks At birth 18 months 
Associated clinical features Headaches, 
pruritus, 
constipationa  
Constipation, 
scoliosis, 
headachesb  
Premature 
birthc, eczema, 
constipation  
Constipation, 
eczema 
Serum biochemistryd:     
Ionized calcium (mmol/L) 1.42 1.41 1.46 1.46 
Phosphate (mmol/L) 0.50 1.98 1.81 1.62 
Alkaline phosphatase (U/L) 77 275 461 243 
Magnesium (mmol/L) 0.78 1.00 0.90 0.93 
Creatinine (µmol/L) 76 26 78 26 
PTH (ng/L) 98 39 100 40 
25-hydroxyvitamin D 
(nmol/L) 
49 50 102 122 
Thyrotropin (mU/L) 2.82 1.83  5.5e  1.53 
Urinary calcium excretion 0.09 0.002 0.001 0.003 
 
aA skin biopsy demonstrated folliculitis with keratin within the widened hair follicle and 
inflammatory cells around the hair follicle. Normal bone mineral density T-score ≥-1.0 at 
lumbar spine and femoral neck. bIndividual III.2 (Figure 1) developed headaches from age 10 
years. cIndividual III.3 was born prematurely at gestational age 27+3 weeks. dNormal 
biochemical ranges: ionized calcium, 1.16-1.30 mmol/L (adults) and 1.16-1.39 mmol/L (age 
1-12 months); phosphate, 1.50-2.60 mmol/L (neonates), 1.50-2.50 mmol/L (age 1-6 months), 
1.20-1.80 mmol/L (age 2-12 years) and 0.71-1.53 mmol/L (adults); alkaline phosphatase 
activity, 35-105 U/L (adults) and 115-460 U/L (age 15 days-1 year); magnesium, 0.71-0.94 
mmol/L (adults) and 0.7-1.0 mmol/L (age 3 months-17 years); creatinine, 60-100 µmol/L 
(adult males) and 10-56 µmol/L (age 8 days-2 years); PTH, 8-73 ng/L; 25-hydroxyvitamin D, 
>50 nmol/L; thyrotropin; 0.5-3.6 mU/L (age >14 weeks) and 0.4-7 mU/L (age 11-14 weeks); 
calcium-to-creatinine clearance ratio >0.02. eTSH concentration measured in umbilical cord 
blood (normal range not available for premature infant cord blood TSH).  
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Figure 2 
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Figure 3 
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